An October 3rd report in Cell and Gene Therapy Insights, a journal publishing the latest cutting edge research and commentary in bioscience, sheds new light on the rapidly expanding potential for CAR-T therapy, which we featured recently in the ACGT blog CAR-T stimulates the immune system to unleash killer T-cells on the cancer, and only the cancer. 
The article cites progress stemming from the cure of a young girl with acute lymphoblastic leukemia in a 2012 trial led by ACGT Scientific Advisory Member, Dr. Carl June, University of Pennsylvania. Since that time, commercial development of the therapy is moving the science from the lab to practice. Read more about the investment community’s take on CAR-T therapy.